A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04210219 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: JNJ-64264681

Sponsor

Janssen Research & Development, LLC